Shenzhen Hepalink Acquires U.S. API Manufacturer Scientific Protein Laboratories
This article was originally published in PharmAsia News
Executive Summary
Shenzhen Hepalink Pharmaceutical acquired 100% of the equity interest of Scientific Protein Laboratories (SLP), a U.S. leading manufacturer of heparin active pharmaceutical ingredients (APIs) for $2.075 billion Jan. 13.
You may also be interested in...
Hepalink-Backed HighTide Bets On NASH For Global Markets
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.